An overview of resistance to Human epidermal growth factor receptor 2(Her2)targeted therapies in breast cancer

作     者：Ahmed M.Elshazly David A.Gewirtz 

作者机构：Department of Pharmacology and ToxicologyFaculty of PharmacyKafrelsheikh UniversityKafrelsheikh 33516Egypt. Department of Pharmacology and ToxicologyVirginia Commonwealth UniversityRichmondVA 23298USA. 

出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)

年 卷 期：2022年第5卷第2期

页      面：472-486页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：National Institutes of Health, NIH National Cancer Institute, NCI, (81XWH19-1-0490, CA260819) California Breast Cancer Research Program, CBCRP 

主　　题：HER2+ Targeted therapy resistance IGF-IR Src c-MET PP2A CD36 miRNA 

摘      要：Breast cancer(BC)is the second most common cause of cancer-related deaths and the most frequently diagnosed cancer in *** breast cancer types,HER2-positive breast cancer occurs in nearly 20%of human breast cancers and is associated with increased aggressiveness,poor prognosis,and shortened overall ***2+breast cancer is currently managed with multidisciplinary treatment strategies including surgery,radiation,chemotherapy,and targeted *** resistance remains a continuing challenge,especially to targeted therapy utilizing monoclonal antibodies and tyrosine kinase *** review discusses some of the recent molecular mechanisms that are involved in the development of resistance to Her2-targeted therapies including the PI3K/Akt/mTOR pathway,IGF-IR,Src,c-MET,the PP2A family,CD36,p27^(kip1),and miRNAs.